We are live on ! Find out more
AA

AlphaCentric Advisors Portfolio holdings

AUM $100M
This Fund
S&P 500
This Quarter Est. Return
+4.14%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$100M
AUM Growth
-$34.3M
Cap. Flow
-$33.3M
Cap. Flow %
-33.2%
Top 10 Hldgs %
26.12%
Holding
294
New
64
Increased
32
Reduced
107
Closed
85

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$5.08M
2
UNH icon
UnitedHealth
UNH
+$4.05M
3
JNJ icon
Johnson & Johnson
JNJ
+$2.82M
4
NVO
Novo Nordisk
NVO
+$2.52M
5
ABBV icon
AbbVie
ABBV
+$2.39M

Top Sells

Rank Stock Value
1
RITM icon
Rithm Capital
RITM
+$4.32M
2
HRMY icon
Harmony Biosciences
HRMY
+$3.88M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$3.12M
4
EFC
Ellington Financial
EFC
+$2.6M
5
MTG icon
MGIC Investment
MTG
+$2.54M

Sector Composition

Rank Sector Weight
1 Healthcare 54.58%
2 Real Estate 7.4%
3 Industrials 5.96%
4 Financials 5.87%
5 Technology 4.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNY icon
276
Sanofi
SNY
$107B
– –
-17,500
Closed -$1.01M
STHO icon
277
Star Holdings Shares of Beneficial Interest
STHO
$114M
– –
-7,744
Closed -$107K
TAK icon
278
Takeda Pharmaceutical
TAK
$54.8B
– –
-80,000
Closed -$1.14M
TRML
279
DELISTED
Tourmaline Bio
TRML
– –
-5,500
Closed -$141K
UTHR icon
280
United Therapeutics
UTHR
$22.7B
– –
-6,250
Closed -$2.24M
VALN
281
Valneva
VALN
$511M
– –
-118,000
Closed -$717K
VERA icon
282
Vera Therapeutics
VERA
$2.76B
– –
-7,500
Closed -$332K
VKTX icon
283
Viking Therapeutics
VKTX
$4.31B
– –
-3,500
Closed -$222K
VNQI icon
284
Vanguard Global ex-US Real Estate ETF
VNQI
$3.49B
– –
-4,021
Closed -$189K
VRDN icon
285
Viridian Therapeutics
VRDN
$1.99B
– –
-15,000
Closed -$341K
VYNE icon
286
VYNE Therapeutics
VYNE
$25.4M
– –
-268,485
Closed -$505K
WIP icon
287
State Street SPDR FTSE International Government Inflation-Protected Bond ETF
WIP
$492M
– –
-2,514
Closed -$101K
AVBP icon
288
ArriVent BioPharma
AVBP
$1.55B
– –
-15,000
Closed -$353K
ONIT
289
Onity Group
ONIT
$344M
– –
-25,567
Closed -$817K
ONC
290
BeOne Medicines Ltd
ONC
$32.4B
– –
-5,500
Closed -$1.23M
ITCI
291
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-20,000
Closed -$1.46M
RVNC
292
DELISTED
Revance Therapeutics, Inc.
RVNC
– –
-245,000
Closed -$1.27M
8 9 10 11
12

Similar funds

WCM
Weber Capital Management San Francisco, California $100M AUM
FCM
Fourier Capital Management Hong Kong $100M AUM
BIA
Baer Investment Advisory Corte Madera, California $100M AUM 23.87% 1-Year Est. Return
AGAM
Audent Global Asset Management West Hollywood, California $100M AUM 22.83% 1-Year Est. Return
E
Entelevest Coral Gables, Florida $100M AUM
HCM
Hicks Capital Management Columbus, Ohio $100M AUM 14.29% 1-Year Est. Return
AC
Arrow Capital Sydney, Australia $100M AUM 68.52% 1-Year Est. Return
OIS
OneAscent Investment Solutions Birmingham, Alabama $100M AUM 15.97% 1-Year Est. Return

AlphaCentric Advisors's Q4 2024 Portfolio in Review

As of Q4 2024, AlphaCentric Advisors held 294 positions worth $100M, down 25% from $135M the previous quarter. Its ten largest holdings account for 26% of the portfolio.

AlphaCentric Advisors withdrew a net $33.3M in Q4 2024, closing 85 positions and reducing 107 holdings. Its most notable exit was Rithm Capital, an estimated $4.32M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 58% a quarter earlier, followed by Real Estate and Industrials.

Against the trend, AlphaCentric Advisors opened a new position in Eli Lilly worth $4.74M.

  • AlphaCentric Advisors's largest Q4 2024 buy was Eli Lilly: 6,140 shares worth $4.74M.
  • AlphaCentric Advisors added most to iShares 1-3 Year Treasury Bond ETF in Q4 2024, an estimated $2.03M increase.
  • AlphaCentric Advisors's biggest Q4 2024 reduction was Neurocrine Biosciences, cutting an estimated $2.33M.
  • AlphaCentric Advisors fully exited Rithm Capital in Q4 2024, selling an estimated $4.32M.
  • AlphaCentric Advisors's ten largest holdings make up 26% of its $100M portfolio in Q4 2024.
  • AlphaCentric Advisors opened 64 new positions and closed 85 in Q4 2024.
  • AlphaCentric Advisors's portfolio value fell 25% quarter-over-quarter to $100M.

Based on AlphaCentric Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.